Novel dual Src/Abl inhibitors for hematologic and solid malignancies

Author： Schenone Silvia   Brullo Chiara   Musumeci Francesca   Botta Maurizio  

Publisher： Informa Healthcare

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.19, Iss.8, 2010-08, pp. : 931-945

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Dual Inhibitors of Src and Abl Tyrosine Kinases

By  

Drug Design Reviews - Online, Vol. 1, Iss. 3, 2004-07 ,pp. : 203-214

Bentham Science Publishers

Access to resources Recommend Favorite

Last Findings on Dual Inhibitors of Abl and Src Tyrosine-Kinases

By  

Mini Reviews in Medicinal Chemistry, Vol. 7, Iss. 2, 2007-02 ,pp. : 191-201

Bentham Science Publishers

Access to resources Recommend Favorite

New SRC/ABL inhibitors for chronic myeloid leukemia therapy show selectivity for T315I ABL mutant CD34+ cells

By Santucci Maria   Mancini Manuela   Corradi Valentina   lacobucci Ilaria   Martinelli Giovanni   Botta Maurizio   Schenone Silvia  

Investigational New Drugs, Vol. 28, Iss. 6, 2010-12 ,pp. : 876-878

Springer Publishing Company

Access to resources Recommend Favorite

Entinostat for treatment of solid tumors and hematologic malignancies

By Knipstein Jeffrey   Gore Lia  

Expert Opinion on Investigational Drugs, Vol. 20, Iss. 10, 2011-10 ,pp. : 1455-1467

Informa Healthcare

Access to resources Recommend Favorite

JAK2 inhibition for the treatment of hematologic and solid malignancies

By Harry Brian L   Eckhardt S. Gail   Jimeno Antonio  

Expert Opinion on Investigational Drugs, Vol. 21, Iss. 5, 2012-05 ,pp. : 637-655

Informa Healthcare

Access to resources Recommend Favorite